The stock has recovered after the recent correction. It has done well and appreciated by around 10% over the last one month. 2013 has been good as it has appreciated by 78%. Growth in the top and the bottom-line has been good over the last few quarters, though the last earnings were not as per expectations. There was some growth in revenues on a yoy basis, but there was decline in net income. Sequentially, there were declines both in the top and the bottom-line. The valuations are a bit higher now, but can improve if the next earnings are better. The P/E (ttm) is around 21.5 and the forward P/E is 16.6. The price to sales ratio is 4.22 and price to book is 2.3. The revenues on a ttm basis are $217 million and the net income is $43 million (20% net profit margin). The good part is that there is no debt and the cash position is strong. It has $259 million cash and the current ratio is 2.5. It is important the Q3 earnings are better than expected. That may give a boost to the sentiments. There has been some insider selling but that could be due to various other reasons. Earnings are to be released in the last week of next month. Analysts are still positive about the stock, and there have been articles recommending to buy the stock. The main reason for the positive stance is the unique business model and the huge potential of the growing market. Spherix (SPEX), which had recently acquired several patents, has filed claims against big companies. One author wrote that RPXC is extremely undervalued because the entire company can be bought for less than the cost of its patent portfolio. RPXC has the expertise to leverage the growth to its advantage.
